Balyasny Asset Management
RIGL icon

Balyasny Asset Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Balyasny Asset Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3,553
Closed -$53.3K – 3074
2022
Q4 		$53.3K Buy
3,553
+644
+22% +$5.9K ﹤0.01% 2345
2022
Q3 		$34K Buy
+2,909
New +$39.3K ﹤0.01% 2519
2022
Q2 		– Sell
-1,549
Closed -$46K – 3103
2022
Q1 		$46K Buy
+1,549
New +$41.9K ﹤0.01% 2242
2019
Q1 		– Sell
-1,152
Closed -$26K – 1612
2018
Q4 		$26K Buy
+1,152
New +$32.5K ﹤0.01% 1341
2018
Q2 		– Sell
-6,755
Closed -$239K – 2089
2018
Q1 		$239K Buy
+6,755
New +$270K ﹤0.01% 1697
2017
Q4 		– Sell
-2,010
Closed -$51K – 2262
2017
Q3 		$51K Buy
+2,010
New +$48.9K ﹤0.01% 1817
2016
Q4 		– Sell
-37,500
Closed -$1.38M – 1461
2016
Q3 		$1.38M Buy
37,500
+35,570
+1,843% +$1.02M 0.01% 655
2016
Q2 		$43K Sell
1,930
-1,916
-50% -$47.6K ﹤0.01% 1121
2016
Q1 		$80K Buy
3,846
+2,314
+151% +$57.1K ﹤0.01% 1215
2015
Q4 		$46K Buy
+1,532
New +$46.4K ﹤0.01% 1189
2015
Q1 		– Sell
-6,377
Closed -$145K – 1055
2014
Q4 		$145K Sell
6,377
-55,623
-90% -$1.12M ﹤0.01% 621
2014
Q3 		$1.2M Buy
+62,000
New +$1.75M 0.01% 649
2014
Q1 		– Sell
-133,804
Closed -$3.81M – 646
2013
Q4 		$3.81M Buy
133,804
+34,430
+35% +$1.01M 0.05% 341
2013
Q3 		$3.56M Buy
99,374
+39,403
+66% +$1.44M 0.05% 396
2013
Q2 		$2M Buy
+59,971
New +$2.72M 0.03% 438

Other funds holding RIGL

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Balyasny Asset Management's RIGL Position: Q1 2023 in Review

Balyasny Asset Management sold out of Rigel Pharmaceuticals (RIGL) in Q1 2023, closing a stake of 3,553 shares — an estimated $53.3K sold.

Balyasny Asset Management first reported a position in RIGL in Q2 2013 and held it in 15 quarters. The position peaked at $3.81M in Q4 2013. 124 funds tracked by Wall St. Rank hold RIGL as of Q1 2023.

  • Balyasny Asset Management reported no remaining Rigel Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Balyasny Asset Management sold 3,553 Rigel Pharmaceuticals shares in Q1 2023, an estimated $53.3K.
  • Balyasny Asset Management first reported a position in Rigel Pharmaceuticals in Q2 2013 and held it in 15 quarters.
  • Balyasny Asset Management's Rigel Pharmaceuticals position peaked at $3.81M in Q4 2013.
  • 124 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2023.

Based on Balyasny Asset Management's 13F filing for Q1 2023, filed 15 May 2023.